Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01283282 · ClinicalTrials.gov registry record · Phase 4
Investigation of the Athero-Protective Effects of Clopidogrel
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 48
- Enrollment target
NCT01283282 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 48 participants.
The verdict
NCT01283282, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 48 participants
- Enrollment target
Study Summary
The investigators would like to investigate whether clopidogrel will help lower the level of harmful markers in patients with coronary artery disease, and at the same time will help increase the cells that are useful in repairing the damaged blood vessels. The investigators will give half of the patients clopidogrel and the other half a sugar pill, placebo, and check the levels of these markers and helpful cells in each group. At the same time the investigators will check how well these patient's blood vessels work using ultrasound imaging of the forearm to see how blood vessels relax and tonometry to see how stiff the patient's blood vessels are. After 6 weeks of drug therapy, the patients will switch to the other drug and these same tests will be performed after an additional 6 weeks of therapy. The drug taken by the patient will not be known to the patient or the researchers. The patients will continue on their prescribed medical therapy during the duration of the 12 week study.
Interventions
- DRUG Placebo
- DRUG Clopidogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01283282
The ClinicalTrials.gov registry entry for NCT01283282 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01283282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01283282 about?
NCT01283282 is a clinical study titled "Investigation of the Athero-Protective Effects of Clopidogrel". The investigators would like to investigate whether clopidogrel will help lower the level of harmful markers in patients with coronary artery disease, and at the same time will help increase the cells that are useful in repairing the damaged blood vessels. The investigators will give half of the pat...
What is the current status of trial NCT01283282?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2008-01. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01283282?
The interventions under investigation include: Placebo (DRUG), Clopidogrel (DRUG).
Who is sponsoring clinical trial NCT01283282?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.